Baidu
map

Lancet Oncol:系统化疗联合西妥昔单抗不能用于早期可切除结肠癌肝转移患者

2020-02-02 MedSci MedSci原创

研究发现,尽管西妥昔单抗-化疗对部分晚期不可切除肿瘤患者有效,但对于早期可切除结肠癌肝转移患者,系统化疗仍是手术后的首选治疗手段

新EPOC研究表明,对于可切除的结肠癌肝转移患者接受西妥昔单抗联合化疗显著缩短了患者无进展生存期,近日研究人员公布了新EPOC研究的总生存结果。

新EPOC III期临床研究中,成年KRAS野生型可切除结肠癌肝转移患者在肝肿瘤切除后随即接受化疗或西妥昔单抗联合化疗,化疗方案为85 mg/m2奥沙利铂静脉滴注2小时、L-亚叶酸(175mg)或DL-亚叶酸(350mg)、氟尿嘧啶(400mg/m2),随后每2周接受2400 mg/m2氟尿嘧啶或每3周接受130 mg/m2的奥沙利铂和卡培他滨。西妥昔单抗的剂量为每2周500 mg/m2。研究的终点为总生存期。

257名患者参与研究,其中西妥昔单抗-化疗组129人,化疗组128人,平均随访66.7个月。化疗组无进展生存期为22.2个月,西妥昔单抗-化疗组为15.5个月。总生存期,化疗组为81个月,西妥昔单抗-化疗组为55.4个月。组间其他次要终点无显著差异。最常见的3-4级不良事件为中性粒细胞计数下降、腹泻、皮疹、血栓栓塞事件、嗜睡和外侧黏膜炎。

研究发现,尽管西妥昔单抗-化疗对部分晚期不可切除肿瘤患者有效,但对于早期可切除结肠癌肝转移患者,系统化疗仍是手术后的首选治疗手段。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1679460, encodeId=854016e9460cb, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90483, encryptionId=d2ea9048398, topicName=西妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271a27776763, createdName=chengjn, createdTime=Tue Jun 09 13:41:00 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865779, encodeId=63771865e79c8, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Sep 05 22:41:00 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830441, encodeId=c3eb1830441f9, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Aug 12 00:41:00 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443852, encodeId=8fac14438522e, content=<a href='/topic/show?id=6b058150307' target=_blank style='color:#2F92EE;'>#肝转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81503, encryptionId=6b058150307, topicName=肝转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea155117075, createdName=ms6747015003810650, createdTime=Tue Feb 04 02:41:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037979, encodeId=bb33103e97953, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sun Feb 02 14:41:00 CST 2020, time=2020-02-02, status=1, ipAttribution=)]
    2020-06-09 chengjn
  2. [GetPortalCommentsPageByObjectIdResponse(id=1679460, encodeId=854016e9460cb, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90483, encryptionId=d2ea9048398, topicName=西妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271a27776763, createdName=chengjn, createdTime=Tue Jun 09 13:41:00 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865779, encodeId=63771865e79c8, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Sep 05 22:41:00 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830441, encodeId=c3eb1830441f9, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Aug 12 00:41:00 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443852, encodeId=8fac14438522e, content=<a href='/topic/show?id=6b058150307' target=_blank style='color:#2F92EE;'>#肝转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81503, encryptionId=6b058150307, topicName=肝转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea155117075, createdName=ms6747015003810650, createdTime=Tue Feb 04 02:41:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037979, encodeId=bb33103e97953, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sun Feb 02 14:41:00 CST 2020, time=2020-02-02, status=1, ipAttribution=)]
    2020-09-05 minlingfeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=1679460, encodeId=854016e9460cb, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90483, encryptionId=d2ea9048398, topicName=西妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271a27776763, createdName=chengjn, createdTime=Tue Jun 09 13:41:00 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865779, encodeId=63771865e79c8, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Sep 05 22:41:00 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830441, encodeId=c3eb1830441f9, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Aug 12 00:41:00 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443852, encodeId=8fac14438522e, content=<a href='/topic/show?id=6b058150307' target=_blank style='color:#2F92EE;'>#肝转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81503, encryptionId=6b058150307, topicName=肝转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea155117075, createdName=ms6747015003810650, createdTime=Tue Feb 04 02:41:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037979, encodeId=bb33103e97953, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sun Feb 02 14:41:00 CST 2020, time=2020-02-02, status=1, ipAttribution=)]
    2020-08-12 howi
  4. [GetPortalCommentsPageByObjectIdResponse(id=1679460, encodeId=854016e9460cb, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90483, encryptionId=d2ea9048398, topicName=西妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271a27776763, createdName=chengjn, createdTime=Tue Jun 09 13:41:00 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865779, encodeId=63771865e79c8, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Sep 05 22:41:00 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830441, encodeId=c3eb1830441f9, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Aug 12 00:41:00 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443852, encodeId=8fac14438522e, content=<a href='/topic/show?id=6b058150307' target=_blank style='color:#2F92EE;'>#肝转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81503, encryptionId=6b058150307, topicName=肝转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea155117075, createdName=ms6747015003810650, createdTime=Tue Feb 04 02:41:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037979, encodeId=bb33103e97953, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sun Feb 02 14:41:00 CST 2020, time=2020-02-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1679460, encodeId=854016e9460cb, content=<a href='/topic/show?id=d2ea9048398' target=_blank style='color:#2F92EE;'>#西妥昔#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90483, encryptionId=d2ea9048398, topicName=西妥昔)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271a27776763, createdName=chengjn, createdTime=Tue Jun 09 13:41:00 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865779, encodeId=63771865e79c8, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Sat Sep 05 22:41:00 CST 2020, time=2020-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830441, encodeId=c3eb1830441f9, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Wed Aug 12 00:41:00 CST 2020, time=2020-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443852, encodeId=8fac14438522e, content=<a href='/topic/show?id=6b058150307' target=_blank style='color:#2F92EE;'>#肝转移#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81503, encryptionId=6b058150307, topicName=肝转移)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea155117075, createdName=ms6747015003810650, createdTime=Tue Feb 04 02:41:00 CST 2020, time=2020-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037979, encodeId=bb33103e97953, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sun Feb 02 14:41:00 CST 2020, time=2020-02-02, status=1, ipAttribution=)]
    2020-02-02 anti-cancer

    谢谢梅斯分享这么多精彩信息

    0

相关资讯

CLIN CANCER RES:miR-31-3p表达可以预测西妥昔单抗疗效

MiR-31-3p表达已被证明与抗EGFR治疗反应有关。CLIN CANCER RES近期发表了一篇文章,研究该生物标志物在FIRE-3研究人群中的预测作用,包括预测接受抗EGFR和抗VEGF治疗的患者预后的能力。

CLIN CANCER RES:Patritumab联合西妥昔单抗和铂类治疗头颈部鳞状细胞癌

CLIN CANCER RES近期发表了一篇文章,研究Patritumab联合西妥昔单抗和铂类治疗头颈部复发和/或转移性(R / M)鳞状细胞癌(SCCHN)患者的的安全性并确定推荐II期联合剂量。

NEJM:Encodrafenib、Binimetinib联合西妥昔单抗用于BRAFV600E突变结直肠癌

研究发现,对于BRAFV600E突变的转移性结直肠癌患者中,Encodrafenib、Binimetinib联合西妥昔单抗组合疗法可延长患者总生存期,提高缓解率

西妥昔单抗联合化疗能使中国复发/转移性头颈部鳞癌患者获益

2018年欧洲肿瘤内科学会亚洲年会(ESMO ASIA 2018)于11月23-25日在新加坡举行。欧洲肿瘤内科学会(ESMO)成立于1975年,是欧洲领先的肿瘤内科学专业组织;2018 ESMO亚洲年会致力于使亚太地区肿瘤学专业人士与快速发展的肿瘤学科学与教育保持同步。在今年的ESMO亚洲年会上,来自上海同济大学附属东方医院的郭晔教授就复发/转移头颈鳞癌的III期CHANGE-2研究结果做了口头

Lancet:西妥昔单抗vs顺铂治疗HPV阳性口咽鳞状细胞癌

研究认为,西妥昔单抗治疗HPV阳性口咽鳞状细胞癌的效果劣于顺铂

郭晔教授:CHANGE-2研究显示——西妥昔单抗联合化疗能使中国复发/转移性头颈部鳞癌患者获益

2018年欧洲肿瘤内科学会亚洲年会(ESMO ASIA 2018)于11月23-25日在新加坡举行。在今年的ESMO亚洲年会上,来自上海同济大学附属东方医院的郭晔教授就复发/转移头颈鳞癌的III期CHANGE-2研究结果做了口头报告。

Baidu
map
Baidu
map
Baidu
map